Thank you very much for the introduction.

Glad to be speaking here and to present some data from our scientific area of the company.

I want to just very briefly talk a bit about the biologic side because that is one that has been very traditional.

But then I want to move into viruses and vaccine development and how we as a company support these efforts from many of our clients.

So just to give you an impression what our business model is looking like,

we are basically founded as a formulation and LIO process development company that is supporting client projects in the areas of formulation and optimisation of formulation and LIO filization.

But also we have a small but growing analytical side and this analytical side is supporting method development and also application of these methods for client samples.

So in principle we have 200 highly qualified employees, most of them with a PhD that are forming our lab workforce.

Many nationalities, we have worked on 725 clients, project managers in the area of more than 1500 projects by now.

And also we have a small scientific part, a small scientific group that is working on developing our own method skills and they have by now worked on 130 publications that have been coming out of this Coriolis structure.

So when we are looking at the method sides and I am responsible for the AUC team at Coriolis,

this AUC team has also been growing now and diversifying into many other methods to take over large parts of the analytical side.

We have traditionally been working a lot in biologics where we supported comparability studies and also method development in these areas.

And AUC, is there a relevant method that is applied frequently?

But in many cases we are fighting a little bit against SAC-MALS, HPLC, other SAC methods and it's not very easy in the biologics field to really, with its many highly developed methods, to find a good place for AUC.

Of course it's there, it is a very relevant method.

We are doing a lot of work on antibodies and a lot of work on peptides also.

But it was very exciting to see then after working with these methods for a long time, to see the development of the gene therapy field,

which now is giving us a huge area of applications, basically not only in peptides, small proteins and large proteins,

but now moving to large systems of viruses, large system of lipid nanoparticles, very complex nanoparticles that have covered surfaces.

So all of these systems are really exciting to work with and that is what I want to focus on today.

How we can bring methods into these fields and how we can support these fields and these projects with the method development in AUC,

but also in some methods around this ecosystem of analytical ultracentrifugation, like orthogonal methods that we can apply.

And the first project that I want to talk about is a virus-based project.

We are sometimes working together with other companies in kind of technology collaborations.

And from these technology collaborations, I can share data.

And in this case, our interest was in applying AUC to make advantage of these characteristics of virus samples.

Virus samples are, of course, much more assembled structures than normal proteins.

The formulation can be a very complex and challenging task, and therefore it's important to have methods available that support these formulation decisions.

Virus samples also are often very rare.

So the amount of virus that is available, clients are very sensitive about the amounts that we spend on viruses.

It's fairly expensive to develop them.

We take some advantage of method development in SAC that is sometimes not easy.

The first virus that I will talk about, AAV, for example, that the SAC still works quite well.

But then when showing the lentivirus data later on, then it is already a big challenge to get other methods to work compared to SVAUC.

SVAUC has a very nice dynamic range.

So while we use the 60,000 for the peptides, we can go down all the way to 3000 for the viruses.

And in some cases, we would even benefit from spinning slower because these viruses are so big,

and sometimes especially when they also aggregate, that it is hard to capture data on the first scan of a virus sample when we are dealing with an aggregation topic.

So best development currently is for AAVs, of course.

And that was also the first project that we did together with Sirion in Martin's Read and also supported by Beckmann.

To just take five AAV zero types and apply several methods to come to a conclusion on how the empty field ratios across that method range would match

and which of the methods is in the end the best one to look at the empty field question and also beyond that.

So the approach that we had been taken is to use these five different zero types,

use an empty sample, use a filled sample and use an in-process sample of each of them and just run it across a panel of methods.

And for us, the charm of these projects is that we can develop a platform of methods to be applied for AAV projects in general.

If we find a general theme within these methods that can connect between them and make a good fitting platform approach.

So the methods we looked at were UV spectroscopy, negative staining electron microscopy, mass photometry, ion exchange chromatography, SV-AUC.

And from a previous publication, we already had compared higher order structure and stability of these AAV zero types with differential scanning fluorometry

and either supported by Dior or not by a Diver Intrinsic.